Evidence map›Paper›PMID 38610968›Full record

ArticleCancers2024

An MRI Radiomics Approach to Predict the Hypercoagulable Status of Gliomas.

Zuzana Saidak, Adrien Laville, Simon Soudet, Marie-Antoinette Sevestre, Jean-Marc Constans, Antoine Galmiche

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Zuzana SaidakUR7516 CHIMERE, Université de Picardie Jules Verne, 80054 Amiens, France.ORCID 0000-0003-4629-1141
Adrien LavilleINSERM UMR 1030, Gustave Roussy Cancer Campus, 94805 Villejuif, France.ORCID 0000-0001-9292-1744
Simon SoudetUR7516 CHIMERE, Université de Picardie Jules Verne, 80054 Amiens, France.ORCID 0000-0001-7003-3703
Marie-Antoinette SevestreUR7516 CHIMERE, Université de Picardie Jules Verne, 80054 Amiens, France.
Jean-Marc ConstansUR7516 CHIMERE, Université de Picardie Jules Verne, 80054 Amiens, France.
Antoine GalmicheUR7516 CHIMERE, Université de Picardie Jules Verne, 80054 Amiens, France.ORCID 0000-0002-5836-4646
Chirurgie et extrémité céphalique, caractérisation morphologique et fonctionnelle · FRCentre Hospitalier Universitaire Amiens-Picardie · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Venous thromboembolic events are frequent complications of Glioblastoma Multiforme (GBM) and low-grade gliomas (LGGs). The overexpression of tissue factor (TF) plays an essential role in the local hypercoagulable phenotype that underlies these complications. Our aim was to build an MRI radiomics model for the non-invasive exploration of the hypercoagulable status of LGG/GBM. Radiogenomics data from The Cancer Genome Atlas (TCGA) and REMBRANDT (Repository for molecular BRAin Neoplasia DaTa) cohorts were used. A logistic regression model (Radscore) was built in order to identify the top 20% TF-expressing tumors, considered to be at high thromboembolic risk. The most contributive MRI radiomics features from LGG/GBM linked to high TF were identified in TCGA using Least Absolute Shrinkage and Selection Operator (LASSO) regression. A logistic regression model was built, whose performance was analyzed with ROC in the TCGA/training and REMBRANDT/validation cohorts: AUC = 0.87 [CI

Indexed as

Glioblastoma Multiformegliomamagnetic resonance imaging (MRI)radiomicstissue factorvenous thromboembolism

Identifiers

PMID38610968
PMCPMC11010849
OpenAlexW4393189233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.